Hi-Tech 'OTC Diet Aid' Could Run Regulatory Risk With Ionamin Brand
This article was originally published in The Tan Sheet
Executive Summary
The firm launches Ionamin as its second weight loss supplement using a brand name once used for a drug as it contests FTC allegations of failing to comply with a settlement not to make unsubstantiated claims.
You may also be interested in...
Blow Tests FDA’s, Industry’s Patience For Illicit Drug-Related Product Brands
Three months after FDA acted on a trade group's complaint and took enforcement action against an energy beverage firm for marketing its product as an alternative to an illicit street drug, the dietary supplement industry has another opportunity to judge how well the agency responds to a firm using drug jargon to market a product
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.